Amycretin is unusual in that it’s being developed as both a daily pill and a weekly injection, and early data suggests the injection produces more weight loss than the pill, though both are substantial. In trials, injectable amycretin has reached weight loss in the low 20% range over several months, while the oral version has produced double-digit results. It’s investigational and not FDA approved. Here’s how the two formats compare and what the numbers look like.<\/p>\n
Amycretin is a single molecule that acts on two targets, the GLP-1 and amylin receptors, combining appetite suppression from two different hormone pathways. What makes it distinctive is that Novo Nordisk is developing it in both a once-weekly subcutaneous injection and a once-daily oral tablet. This gives potential patients a choice: the convenience of a pill or the typically stronger effect of an injection.<\/p>\n
The reason a drug can work in both forms is a matter of how much reaches your bloodstream. Injections deliver the drug efficiently, while oral peptide-style drugs face the challenge of surviving digestion, which usually means higher doses are needed and somewhat less predictable absorption. That difference tends to show up in the results.<\/p>\n